The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data

Journal of Chemotherapy

Volumn 11, Issue 2, 1999, Pages 107-118

  Carbon, C ^a   Poole, M D ^b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Antimicrobial drug resistance; Azithromycin; Clarithromycin; Macrolides; Respiratory tract infection

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; MACROLIDE;

ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG EFFICACY; EXTRACELLULAR SPACE; HAEMOPHILUS INFLUENZAE; HYPOTHESIS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; OTITIS MEDIA; PH; PHARYNGITIS; PREVALENCE; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TREATMENT INDICATION;

EID: 0032894333     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.2.107     Document Type: Article

References (77)

1. 1 Bryskier A, Agouridas C, Gasc JC. Classification of macrolide antibiotics. In: Bryskier A, Butzler JP, Neu HC, Tulkens MP, eds. Macrolides: chemistry, pharmacology and clinical use. Oxford, England: Blackwell 1993: 5-66.
2. 2 Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 1992; 26: 46-55.
3. 3 Kanatani MS, Guglielmo BJ. The new macrolides azithromycin and clarithromycin. West J Med 1994; 160: 31-37.
4. 4 Zuckerman JM, Kaye KM. The new macrolides: azithromycin and clarithromycin. Infect Dis Clin North Am 1995; 9: 731-745.
5. 5 American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-1426.
6. 6 British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346-350.
7. 7 Langtry HD, Brogden RN. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs 1997; 53: 973-1004.
8. 8 Ednie LM, Visalli MA, Jacobs MR et al. Comparative activities of clarithromycin, erythromycin and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob Agents Chemother 1996; 40: 1950-1952.
9. 9 Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108 (Suppl): 43S-52S.
10. 10 Centers for Disease Control and Prevention: Drug-resistant S. pneumoniae - Kentucky and Tennessee. MMWR 1994; 43: 23.
11. 11 Seppala H, Nissinen A, Jarvinen H et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992; 326: 292.
12. 12 Breiman RF, Butler JC, Tenover FC et al. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994; 271: 1831-1835.
13. 13 Doern GV, Brueggemann, Holley HP et al. Antimicrobial resistance of S. pneumoniae recovered from outpatients in the US during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40: 1208-1213.
14. 14 Barry AL, Fuchs PC, Brown SD. Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA. J Antimicrob Chemother 1997; 40: 139-140.
15. 15 Marchese A, Debbia E, Pesce A, Schito GC. Comparative activities of amoxycillin and 10 other oral drugs against penicillin-susceptible and resistant S. pneumoniae strains recently isolated in Italy. Clin Microbiol Infect 1998; 4: 170-173.
16. 16 Linares J, Tubau F. Meningitis neumococica y cefalosporinas de tercera generacion. Enferm Infecc Microbiol Clin 1996; 14: 1-6.
17. 17 Martinez-Martinez L, Lopez-Hernandez I, Pascual A et al. Resistance of S. pneumoniae to penicillin, erythromycin and third generation cephalosporins in Seville, Southern Spain. Clin Microbiol Infect 1997; 3: 382-385.
18. 18 Felmingham D, Gruneberg RN. Comparative in vitro activity of 16 antimicrobials against 5442 community-acquired, lower respiratory tract pathogens: The Alexander Project 1997. 36th IDSA, Denver; 1998: Abstract no 198 [Fr].
19. 19 Nakae M, Murai T, Kaneko Y et al. Drug resistance in S. pyogenes isolated in Japan (1974-1975). Antimicrob Agents Chemother 1977; 12: 427-428.
20. 20 Fujita K, Murono K, Yoshikawa M et al. Decline of erythromycin resistance of group A streptococci in Japan. Pediatr Infect Dis 1994; 13: 1075-1078.
21. 21 Seppala H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337: 441-446.
22. 22 Perez-Trallero E, Urbiena M, Montes M, Ayestaran I et al. Emergence of S. pyogenes strains resistant to erythromycin in Gipuzkoa, Spain. Eur J Clin Microbiol Dis 1998; 17: 25-31.
23. 23 Cornaglia G, Ligozzi M, Mazzariol A et al. Rapid increase of resistance to erythromycin and clindamycin in S. pyogenes in Italy, 1993-1995. Emerg Infect Dis 1996; 2: 339-343.
24. 24 Borzani M, De Luca M, Varotto F. A survey of susceptibility to erythromycin amongst S. pyogenes isolates in Italy. J Antimicrob Chemother 1997; 40: 457-458.
25. 25 Cocuzza CE, Mattina R, Mazzariol A et al. High incidence of erythromycin-resistant S. pyogenes in Monza (Northern Italy) in untreated children with symptoms of acute pharyngotonsillitis: an epidemiological and molecular study. Microbiol Drug Res 1997; 3: 371-378.
26. 26 Hardy DJ, Swanson RN, Rode RA et al. Enhancement of the in vitro and in vivo activities of clarithromycin against H. influenzae by 14-hydroxy-clarithromycin its major metabolite in humans. Antimicrob Agents Chemother 1990; 34: 1407-1413.
27. 27 Olsson-Liljequist B, Hoffman BM. In vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae. J Antimicrob Chemother 1991; 27 (Suppl A): 11-17.
28. 28 Jorgensen JH, Maher LA, Howell AW. Activity of clarithromycin and its principal human metabolite against H. influenzae. Antimicrob Agents Chemother 1991; 35: 1524-1526.
29. 29 Haight TH, Finland M. The antibacterial action of erythromycin. Proc Soc Exp Biol Med 1952; 81: 175-183.
30. 30 Schlossberg D. Azithromycin and clarithromycin. Med Clin North Am 1995; 79: 803-815.
31. 31 Jossart GH, Erdman GR, Steury JC et al. Effects of pH and protein binding on middle ear antimicrobial drug penetration may explain acute otitis media treatment failures. In: Lim DJ, Bluestone CD, Klein JO, Nelson JD, Orga PL, eds. Recent Advances in Otitis Media. Proceedings of the Fifth International Symposium. Fort Lauderdale: Decker Periodicals, 1991: 446-449.
32. 32 Bodem CR, Lampton LM, Miller DP, Tarka EF, Everett ED. Endobronchial pH. Relevance to aminoglycoside activity in Gram-negative bacillary pneumonia. Am Rev Respir Dis 1983; 127: 39-41.
33. 33 Garrison MW, Malone CL, Eiland J et al. Influence of pH on the antimicrobial activity of clarithromycin and 14-hydroxyclarithromycin against H. influenzae using an in vitro pharmacodynamic model. Diagn Microbiol Infect Dis 1997; 27: 139-145.
34. 34 Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 (Suppl A): 73-82.
35. 35 Washington JM, Wilson WR. Erythromycin: a microbial and clinical perspective after 30 years of clinical use. Mayo Clin Proc 1985; 60: 189-203.
36. 36 Kohno Y, Ohta K, Suwa K et al. Autobacteriographic studies of clarithromycin and erythromycin in mice. Antimicrob Agents Chemother 1990; 34: 562-567.
37. 37 Krohn K. Gynaecological tissue levels of azithromycin. Eur J Clin Microbiol Infect Dis 1991; 10: 864-868.
38. 38 Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clin Infect Dis 1998; 26: 1-12.
39. 39 Barza M, Cuchural G. General principles of antibiotic tissue penetration. J Antimicrob Chemother 1985; 15 (Suppl A): 59-75.
40. 40 Ryan DM, Cars O. A problem in the interpretation of beta lactam antibiotic levels in tissues. J Antimicrob Chemother 1983; 12: 281-284.
41. 41 Carbon C. Pharmacodynamics of macrolides, azalides and streptogramins: effect on extracellular pathogens. Clin Inf Dis 1998; 27: 28-32.
42. 12 Barza M. Approaches to the measurement of antibiotic concentrations in tissues. Res Clin Forums 1990; 12: 15-22.
43. 43 Honeybourne D, Baldwin DR. The site concentrations of antimicrobial agents in the lung. J Antimicrob Chemother 1992; 30: 249-260.
44. 44 Conte JE, Golden J, Duncan S et al. Single dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin and cefuroxime in volunteer subjects. Antimicrob Agents Chemother 1996; 40: 1617-1622.
45. 45 Patel KB, Xuan D, Tessier PR et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996; 40: 2375-2379.
46. 46 Johnson JD, Hand WL, Francis JB, King-Thompson N, Corwin RW. Antibiotic uptake by alveolar macrophages. J Lab Clin Med 1980; 95: 429-439.
47. 47 Panteix G, Guillaumond B, Harf R et al. In vitro concentration of azithromycin in human phagocytic cells. J Antimicrob Chemother 1993; 31 (Suppl E): 1-4.
48. 48 Gan VN, McCarty JM, Chu SY et al. Penetration of clarithromycin into middle ear fluid of children with acute otitis media. Pediatr Infect Dis J 1997; 16: 39-43.
49. 49 Pukander J, Rautianen M. Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. J Antimicrob Chemother 1996; 37 (Suppl C): 53-61.
50. 50 Girard AE, Cimochowski CR, Faiella JA. Correlation of increased azithromycin concentrations with phagocytic infiltration into sites of localised infection. J Antimicrob Chemother 1996; 37 (Suppl C): 9-19.
51. 51 Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989; 33: 277-282.
52. 52 Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991; 91 (Suppl A): 5-11.
53. 53 Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992; 44: 750-799.
54. 54 Langtry HD, Brogden RN. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs 1997; 53: 973-1004.
55. 55 McLinn S. Double blind and open label studies of azithromycin in management of acute otitis media in children: a review. Pediatr Inf Dis J 1995; 14 (Suppl): S62-66.
56. 56 Niedermann MS, Bass JB, Campbell GD et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-1426.
57. 57 Woodhead M. Community-acquired pneumonia guidelines - An international comparison. Chest 1998; 113 (Suppl 3): 183S-187S.
58. 58 Bartlett JG, Breiman RF, Mandell LA, File TM. Community-acquired pneumonia in adults: Guidelines for management. Clin Infect Dis 1998; 26: 811-838.
59. 59 Rello J. Prescriptions of macrolides in community-acquired pneumonia. Chest 1998; 113: 1155-1158.
60. 60 Fogarty C. Bacteremic treatment failure with azithromycin in community-acquired pneumococcal pneumonia: a report of 3 patients infected with erythromycin-resistant and penicillin-and cephalosporin-nonsusceptible strains treated successfully with levofloxacin. ICAAC 1998, San Diego: Abstract L-102.
61. 61 Ortqvist A, Valtonen M, Cars O et al. Oral empiric treatment of community-acquired pneumonia. Chest 1996; 110: 1499-1506.
62. 62 Edelstein PH Antimicrobial chemotherapy for Legoinnaires' disease: Time for a change. Ann Intern Med 1998; 129: 328-330.
63. 63 Beghi G, Berni F, Carratu L et al. Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis. J Chemother 1995; 7: 146-152.
64. 64 Davies BI, Maesen FPV, Gubbelmans R. Azithromycin in acute exacerbations of chronic bronchitis: an open clinical, microbiological and pharmacokinetic study. J Antimicrob Chemother 1989; 23: 743-751.
65. 65 Ginsburg CM, Eichenwald HF. Erythromycin: a review of its uses in pediatric practice. J Pediatr 1976; 89: 872-884.
66. 66 Mohs E, Rodriguez-Solares E, Rivas E, El Hoshy Z. A comparative study of azithromycin and amoxycillin in paediatric patients with acute otitis media. J Antimicrob Chemother 1993; 31 (Suppl E): 73-79.
67. 67 Schaad UB. Multicentre evaluation of azithromycin in comparison with co-amoxyclav for the treatment of acute otitis media in children. J Antimicrob Chemother 1993; 31 (Suppl E): 81-88.
68. 68 Fasola EL, Bajaksouzian S, Appelbaum PC, Jacobs MR. Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods. Antimicrob Agents Chemother 1997; 41: 129-134.
69. 69 Dagan R, Piglansky L, Yagupsky P et al. Bacteriologic response in acute otitis media: comparison between azithromycin, cefaclor and amoxicillin. ICAAC 1997, Toronto: Abstract K-103.
70. 70 Dagan R, Leibovitz E, Jacobs M et al. Bacteriologic response to acute otitis media caused by H. influenzae treated with azithromycin. ICAAC 1997, Toronto: Abstract K-102.
71. 71 Dagan R, Leibovitz E, Greenberg D et al. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatr Infect Dis J 1998; 17: 776-782.
72. 72 Brook I, Gober AE. Microbiology of persistent otitis media. ICAAC 1998, San Diego: Abstract MN-35.
73. 73 Sundberg L, Cederberg A. Penetration of clarithromycin and its 14-hydroxy metabolite into middle ear effusion in children with secretory otitis media. J Antimicrob Chemother 1994; 33: 299-307.
74. 74 Hamill J. Multicentre evaluation of azithromycin and penicillin V in the treatment of acute Streptococcal pharyngitis and tonsillitis in children. J Antimicrob Chemother 1993; 31 (Suppl E): 89-94.
75. 75 Carbon C, Hotton JM, Pepin LF et al. Economic analysis of antibiotic regimens used in the treatment of pharyngitis: a prospective comparison of azithromycin versus roxithromycin. J Antimicrob Chemother 1996; 37 (Suppl C): 151-161.
76. 76 Schaad UB, Heynen G. Evaluation of the efficacy, safety and toleration of azithromycin vs penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study. Pediatr Infect Dis J 1996; 15: 791-795.
77. 77 Pacifico L, Scopetti F, Ranucci A et al. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. Antimicrob Agents Chemother 1996; 40: 1005-1008.